New antibiotic TQD3524 tested in kidney patients for tough infections
NCT ID NCT06522945
First seen Jan 10, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This completed Phase 1 study looked at how the antibiotic TQD3524 behaves in 48 people with kidney problems who have drug-resistant bacterial infections. Researchers measured drug levels in the blood and urine after a single dose to understand safety and how the body processes the drug. The goal was to gather information for future dosing recommendations, not to treat the infection itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Jinan, Shandong, 250000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQD3524 (a polymyxin antibiotic)
What this could lead to
If successful, this could help doctors understand how to safely dose TQD3524 in patients with kidney problems, potentially improving treatment for drug-resistant infections.
What could go wrong
This is an early Phase 1 study focused on safety and drug levels, not on curing infections. It is small (48 people) and completed, so results may not apply broadly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.